Plain-English translation of NCT05413057 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a large observational study that will follow about 20,000 people with high blood pressure who are being treated with fimasartan/amlodipine or fimasartan/amlodipine/hydrochlorothiazide. Researchers want to understand how well this medication combination works in real-world clinical settings and whether it's safe for everyday use. You won't be asked to do anything special — doctors will simply track your health and blood pressure readings over time.
While these medication combinations are prescribed for high blood pressure, researchers want to gather real-world data from thousands of patients to confirm the medication is effective and safe across different groups of people and settings.
You likely qualify if…
You likely don't qualify if…
You will visit your doctor at participating medical centers, and your doctor will track your blood pressure, medical history, current medications, and any side effects you experience. The study takes place at about 600 hospitals and clinics across the country. You won't need to take any new medications — researchers will simply monitor your blood pressure control and health while you take the medication your doctor has prescribed, and collect information about your cardiovascular health over the study period.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
South Korea
Sponsor
Boryung Pharmaceutical Co., Ltd
Enrollment target
~20,000 participants
Started
June 2022
Primary completion
June 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
19 Years and older
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
MyungSook Hong
Boryung Co.,Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.